Ectopically Expressed Membrane-bound Form of IL-9 Exerts Immune-stimulatory Effect on CT26 Colon Carcinoma Cells
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
IL-9 is a known T cell growth factor with pleiotropic immunological functions, especially in parasite infection and colitis. However, its role in tumor growth is controversial. In this study, we generated tumor clones expressing the membrane-bound form of IL-9 (MB-IL-9) and investigated their influences on immune system. MB-IL-9 tumor clones showed reduced tumorigenicity but shortened survival accompanied with severe body weight loss in mice. MB-IL-9 expression on tumor cells had no effect on cell proliferation or major histocompatibility complex class I expression in vitro. MB-IL-9 tumor clones were effective in amplifying CD4+ and CD8+ T cells and increasing cytotoxic activity against CT26 cells in vivo. We also observed a prominent reduction in body weights and survival period of mice injected intraperitoneally with MB-IL-9 clones compared with control groups. Ratios of IL-17 to interferon (IFN)-γ in serum level and tumor mass were higher in mice implanted with MB-IL-9 tumor clones than those observed in mice implanted with control cells. These results indicate that the ectopic expression of the MB-IL-9 on tumor cells exerts an immune-stimulatory effect with toxicity. To exploit its benefits as a tumor vaccine, a strategy to control the toxicity of MB-IL-9 tumor clones should be developed.
Abstract
IL-9 is a known T cell growth factor with pleiotropic immunological functions, especially in parasite infection and colitis. However, its role in tumor growth is controversial. In this study, we generated tumor clones expressing the membrane-bound form of IL-9 (MB-IL-9) and investigated their influences on immune system. MB-IL-9 tumor clones showed reduced tumorigenicity but shortened survival accompanied with severe body weight loss in mice. MB-IL-9 expression on tumor cells had no effect on cell proliferation or major histocompatibility complex class I expression in vitro. MB-IL-9 tumor clones were effective in amplifying CD4+ and CD8+ T cells and increasing cytotoxic activity against CT26 cells in vivo. We also observed a prominent reduction in body weights and survival period of mice injected intraperitoneally with MB-IL-9 clones compared with control groups. Ratios of IL-17 to interferon (IFN)-γ in serum level and tumor mass were higher in mice implanted with MB-IL-9 tumor clones than those observed in mice implanted with control cells. These results indicate that the ectopic expression of the MB-IL-9 on tumor cells exerts an immune-stimulatory effect with toxicity. To exploit its benefits as a tumor vaccine, a strategy to control the toxicity of MB-IL-9 tumor clones should be developed.
참고문헌 (40)
- Uyttenhove C, "Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity", Proc Natl Acad Sci U S A, 85, pp.6934~6938 (1988)[DOI]
- Schmitt E, "Amazing IL-9: revealing a new function for an old cytokine", J Clin Invest, 122, pp.3857~3859 (2012)[DOI]
- Renauld JC, "Thymic lymphomas in interleukin 9 transgenic mice", Oncogene, 9, pp.1327~1332 (1994)
- Veldhoen M, "Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset", Nat Immunol, 9, pp.1341~1346 (2008)[DOI]
- Dardalhon V, "IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells", Nat Immunol, 9, pp.1347~1355 (2008)[DOI]
- Beriou G, "TGF-beta induces IL-9 production from human Th17 cells", J Immunol, 185, pp.46~54 (2010)[DOI]
- Lu LF, "Mast cells are essential intermediaries in regulatory T-cell tolerance", Nature, 442, pp.997~1002 (2006)[DOI]
- Stassen M, "From interleukin-9 to T helper 9 cells", Ann N Y Acad Sci, 1247, pp.56~68 (2012)[DOI]
- Chang HC, "The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation", Nat Immunol, 11, pp.527~534 (2010)[DOI]
- Brustle A, "The development of inflammatory T(h)-17 cells requires interferon-regulatory factor 4", Nat Immunol, 8, pp.958~966 (2007)[DOI]
- Purwar R, "Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells", Nat Med, 18, pp.1248~1253 (2012)[DOI]
- Kim IK, "Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells", Nat Med, 21, pp.1010~1017 (2015)[DOI]
- Parrot T, "IL-9 promotes the survival and function of human melanoma-infiltrating CD4(+) CD8(+) double-positive T cells", Eur J Immunol, 46, pp.1770~1782 (2016)[DOI]
- Fang Y, "IL-9 inhibits HTB-72 melanoma cell growth through upregulation of p21 and TRAIL", J Surg Oncol, 111, pp.969~974 (2015)[DOI]
- Lu Y, "Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers", Proc Natl Acad Sci U S A, 111, pp.2265~2270 (2014)[DOI]
- Lu Y, "Th9 cells promote antitumor immune responses in vivo", J Clin Invest, 122, pp.4160~4171 (2012)[DOI]
- Liu JQ, "Tumor-specific Th2 responses inhibit growth of CT26 colon-cancer cells in mice via converting intratumor regulatory T cells to Th9 cells", Sci Rep, 5, pp.10665~ (2015)[DOI]
- Rivera Vargas T, "TH9 cells in anti-tumor immunity", Semin Immunopathol, 39, pp.39~46 (2017)[DOI]
- Huang Y, "Association between low expression levels of interleukin-9 and colon cancer progression", Exp Ther Med, 10, pp.942~946 (2015)[DOI]
- Zhao Y, "Dectin-1-activated dendritic cells trigger potent antitumour immunity through the induction of Th9 cells", Nat Commun, 7, pp.12368~ (2016)[DOI]
- Nakatsukasa H, "The DNA-binding inhibitor Id3 regulates IL-9 production in CD4(+) T cells", Nat Immunol, 16, pp.1077~1084 (2015)[DOI]
- Grimbaldeston MA, "Mast cell-deficient W-sash c-kit mutant Kit W-sh", W-sh mice as a model for investigating mast cell biology in vivo, 2005, pp.167, 835~848
- Abdul-Wahid A, "Induction of antigen-specific TH 9 immunity accompanied by mast cell activation blocks tumor cell engraftment", Int J Cancer, 139, pp.841~853 (2016)[DOI]
- Hoelzinger DB, "Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges", Cancer Res, 74, pp.6845~6855 (2014)[DOI]
- Lv X, "Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma", J Exp Clin Cancer Res, 35, pp.106~ (2016)[DOI]
- Zhang J, "Serum levels of interleukin-9 correlate with negative prognostic factors in extranodal NK", T-cell lymphoma, 2014, pp.9, e94637~
- Knoops L, "IL-9 and its receptor: from signal transduction to tumorigenesis", Growth Factors, 22, pp.207~215 (2004)[DOI]
- Fischer M, "Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma", Leukemia, 17, pp.2513~2516 (2003)[DOI]
- Chen N, "Overexpression of IL-9 induced by STAT6 activation promotes the pathogenesis of chronic lymphocytic leukemia", Int J Clin Exp Pathol, 7, pp.2319~2323 (2014)
- Elyaman W, "IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells", Proc Natl Acad Sci U S A, 106, pp.12885~12890 (2009)[DOI]
- 김영상, "Tumor Therapy Applying Membrane-bound Form of Cytokines", Immune Network, 9(5), pp.158~168 (2009), 대한면역학회
- Van Anh Do Thi, "The Membrane-Bound Form of IL-17A Promotes the Growth and Tumorigenicity of Colon Cancer Cells", Molecules and Cells, 39(7), pp.536~542 (2016), 한국분자세포생물학회[DOI]
- Horiuchi T, "Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents", Rheumatology (Oxford), 49, pp.1215~1228 (2010)[DOI]
- Vayrynen JP, "The relationships between serum cytokine levels and tumor infiltrating immune cells and their clinical significance in colorectal cancer", Int J Cancer, 139, pp.112~121 (2016)[DOI]
- Leung S, "The cytokine milieu in the interplay of pathogenic Th1", Th17 cells and regulatory T cells in autoimmune disease, 2010, pp.7, 182~189
- Lundy SK, "Reduced Fas ligand-expressing splenic CD5+ B lymphocytes in severe collagen-induced arthritis", Arthritis Res Ther, 11, pp.R128~ (2009)[DOI]
- 장미라, "Antitumor immunity induced by tumor cells engineered to express a membrane-bound form of IL-2", Experimental and Molecular Medicine, 37(3), pp.240~249 (2005), 생화학분자생물학회
- 김현진, "Membrane-bound p35 Subunit of IL-12 on Tumor Cells is Functionally Equivalent to Membrane-bound Heterodimeric Single Chain IL-12 for Induction of Anti-tumor Immunity", Immune Network, 16(5), pp.305~310 (2016), 대한면역학회[DOI]
- Kim YS, "Tumor cells expressing membrane-bound form of IL-4 induce antitumor immunity", Gene Ther, 7, pp.837~843 (2000)[DOI]
- Lim HY, "Antitumor effects of a tumor cell vaccine expressing a membrane-bound form of the IL-12 p35 subunit", Cancer Biol Ther, 10, pp.336~343 (2010)[DOI]